Amyloid PET in Alzheimer research

Brain and Nerve

Volumn 62, Issue 7, 2010, Pages 757-767

  Ishii, Kenji ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Alzheimer disease; Amyloid imaging; Amyloid beta; MCI; PET; PiB

Indexed keywords

AMYLOID BETA PROTEIN; AV 45; BAPINEUZUMAB; BF 227; BIOLOGICAL MARKER; CARBON 11; CONGO RED; FLUORINE 18; PITTSBURGH COMPOUND B; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; CARBON; DIETHYL-1,3,6,8-TETRAHYDRO-1,3,6,8-TETRAOXOBENZO(LMN)(3,8)PHENANTHROLINE-2,7-DIACETATE; PHENANTHROLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; TAUOPATHY; DIAGNOSTIC USE; METABOLISM; PROCEDURES; RHOMBENCEPHALON; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; HUMANS; PHENANTHROLINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RHOMBENCEPHALON; AMYLOID BETA-PEPTIDES;

EID: 77955402164     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Klunk WE, Mathis CA: The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 21: 683-687, 2008
2. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, et al: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35, 2002
3. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, et al: PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652-2663, 2006
4. Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, et al: Molecular-imaging probe 2-(1- [6- [(2-fluoroethyl)(methyl) amino] -2-naphthyl] ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 23: 8029-8033, 2003
5. Boxer AL, Rabinovici GD, Kepe V, Goldman J, Furst AJ, et al: Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 69: 283-290, 2007
6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319, 2004
7. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, et al: 2-(2- [2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2- [fluoro] ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48: 553-561, 2007
8. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, et al: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131: 1630-1645, 2008
9. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, et al: In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27: 10365-10371, 2007
10. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, et al: The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21: 672-687, 2009
11. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, et al: Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62: 229-234, 2007
12. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, et al: Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64: 431-434, 2007
13. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, et al: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25: 1528-1547, 2005
14. 11C] PIB studies. Neuroimage 42: 76-86, 2008
15. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, et al: Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46: 1959-1972, 2005
16. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68: 1205-1212, 2007
17. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680, 2008
18. 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 48: 547-552, 2007
19. 18F] FDG PET study. Neurology 68: 501-508, 2007
20. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, et al: Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 65: 1304-1309, 2008
21. Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, et al: Cortical alpha7 nicotinic acetyl-choline receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66: 646-651, 2009
22. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, et al: Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606, 2005
23. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 68: 1718-1725, 2007
24. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259, 1991
25. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, et al: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27: 6174-6184, 2007
26. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, et al: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130: 2837-2844, 2007
27. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, et al: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856-2866, 2006
28. Kemppainen NM, Aalto S, Karrasch M, Någren K, Savisto N, et al: Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 63: 112-118, 2008
29. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, et al: Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29: 1860-1873, 2009
30. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, et al: Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63: 178-188, 2009
31. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, et al: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465, 2008
32. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al: Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132: 1310-1323, 2009
33. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, et al: PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment. Neurology 68: 1603-1606, 2007
34. Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, et al: PET amyloid ligand [11C] PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 26: 378-383, 2008
35. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, et al: Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66: 1837-1844, 2006
36. Price JL, Morris JC: Tangles and plaques in non-demented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368, 1999
37. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, et al: Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57: 1168-1174, 1998
38. 11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452, 2006
39. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517, 2008
40. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al: Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132: 1310-1323, 2009
41. Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 6820-6825, 2009
42. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, et al: Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46: 1688-1697, 2008
43. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL: Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 65: 113-120, 2008
44. Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, et al: Lack of association between (11) C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging. 2010 [Epub ahead of print]
45. Morris JC, Roe CM, Grant EA, Head D, Storandt M, et al: Pittsburgh cmpound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66: 1469-1475, 2009
46. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519, 2006
47. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, et al: Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65: 927-934, 2009
48. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, et al: Absence of Pittsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease. Arch Neurol 66:1557-1562, 2009
49. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, et al: Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39: 619-633, 2008
50. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, et al: In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35: 100-106, 2008
51. 11C] -PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord 14: 345-347, 2008
52. 11C] PIB binding in Parkinson's disease dementia. Neuroimage 39: 1027-1033, 2008
53. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, et al: Imaging amyloid deposition in Lewy body diseases. Neurology 71: 903-910, 2008
54. 11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338, 2008
55. Ng SY, Villemagne VL, Masters CL, Rowe CC: Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 64: 1140-1144, 2007
56. Kambe T, Motoi Y, Ishii K, Hattori N: Carbon 11-labeled Pittsburgh Compound B accumulation in the occipital cortex in posterior cortical atrophy. J Neurology. (in press),
57. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562, 2005
58. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003
59. Masliah E, Hansen L, Adame A, Crews L, Bard F, et al: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131, 2005
60. Mathis CA, Lopresti BJ, Klunk WE: Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34: 809-822, 2007
61. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365, 2009
62. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372, 2010
63. 18F- flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50: 1251-1259, 2009
64. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7: 129-135, 2008
65. 18F-AV-45 (flobetapir F 18). J Nucl Med 51: 913-920, 2010
66. Talan J: Neuroimaging tracers for AD detection not yet ready for prime time, FDA Panel advises. Neurology Today 8: 1-8, 2008